Amedeo Smart

Free Medical Literature Service


 

Amedeo

Breast Cancer

  Free Subscription

Articles published in
J Natl Cancer Inst
    April 2018
  1. CHOI HJ, Joo HS, Won HY, Min KW, et al
    Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
    J Natl Cancer Inst. 2018;110.
    >> Share

  2. VERMA V, Simone CB 2nd, Mishra MV
    Quality of Life and Patient-Reported Outcomes Following Proton Radiation Therapy: A Systematic Review.
    J Natl Cancer Inst. 2018;110.
    >> Share

    February 2018
  3. HEINDL A, Sestak I, Naidoo K, Cuzick J, et al
    Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer.
    J Natl Cancer Inst. 2018;110.
    >> Share

  4. TROESTER MA, Sun X, Allott EH, Geradts J, et al
    Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study.
    J Natl Cancer Inst. 2018;110.
    >> Share

  5. BANDOS H, Melnikow J, Rivera DR, Swain SM, et al
    Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30.
    J Natl Cancer Inst. 2018;110.
    >> Share

  6. RIVERA DR, Ganz PA, Weyrich MS, Bandos H, et al
    Chemotherapy-Associated Peripheral Neuropathy in Patients With Early-Stage Breast Cancer: A Systematic Review.
    J Natl Cancer Inst. 2018;110.
    >> Share

  7. JAGSI R, Momoh AO, Qi J, Hamill JB, et al
    Impact of Radiotherapy on Complications and Patient-Reported Outcomes After Breast Reconstruction.
    J Natl Cancer Inst. 2018;110.
    >> Share

    January 2018
  8. SCHRIJVER WAME, Suijkerbuijk KPM, van Gils CH, van der Wall E, et al
    Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis.
    J Natl Cancer Inst. 2018 Jan 5. pii: 4791841. doi: 10.1093.
    >> Share

  9. BLOK EJ, Kroep JR, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, et al
    Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05).
    J Natl Cancer Inst. 2018;110.
    >> Share

  10. GOLDVASER H, Barnes TA, Seruga B, Cescon DW, et al
    Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis.
    J Natl Cancer Inst. 2018;110.
    >> Share

  11. JOHNSON SB, Park HS, Gross CP, Yu JB, et al
    Use of Alternative Medicine for Cancer and Its Impact on Survival.
    J Natl Cancer Inst. 2018;110.
    >> Share

    December 2017
  12. POORVU PD, Winer EP
    Adjuvant Chemotherapy for ER+ Breast Cancer: A Sea Change is Underway.
    J Natl Cancer Inst. 2017 Dec 11. pii: 4718502. doi: 10.1093.
    >> Share

  13. KURIAN AW, Bondarenko I, Jagsi R, Friese CR, et al
    Recent Trends in Chemotherapy Use and Oncologists' Treatment Recommendations for Early-Stage Breast Cancer.
    J Natl Cancer Inst. 2017 Dec 11. pii: 4718501. doi: 10.1093.
    >> Share

  14. GLUZ O, Nitz U, Liedtke C, Christgen M, et al
    Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results.
    J Natl Cancer Inst. 2017 Dec 8. pii: 4698155. doi: 10.1093.
    >> Share

    November 2017
  15. BELKACEMI Y, Kuten A
    RE: Regional Nodal Irradiation After Breast-Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial.
    J Natl Cancer Inst. 2017 Nov 21. pii: 4645256. doi: 10.1093.
    >> Share

  16. MEIER M, Orr N
    Genetic Determinants of Breast Cancer Risk in Childhood Cancer Survivors.
    J Natl Cancer Inst. 2017;109.
    >> Share

  17. MORTON LM, Sampson JN, Armstrong GT, Chen TH, et al
    Genome-Wide Association Study to Identify Susceptibility Loci That Modify Radiation-Related Risk for Breast Cancer After Childhood Cancer.
    J Natl Cancer Inst. 2017;109.
    >> Share

  18. DESHMUKH AA, Shirvani SM, Lal L, Swint JM, et al
    Cost-effectiveness Analysis Comparing Conventional, Hypofractionated, and Intraoperative Radiotherapy for Early-Stage Breast Cancer.
    J Natl Cancer Inst. 2017;109.
    >> Share

  19. SCHWARZ LJ, Hutchinson KE, Rexer BN, Estrada MV, et al
    An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
    J Natl Cancer Inst. 2017;109.
    >> Share

    October 2017
  20. LAMBERTINI M, Kroman N, Ameye L, Cordoba O, et al
    Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status.
    J Natl Cancer Inst. 2017 Oct 26. doi: 10.1093.
    >> Share

  21. VISSCHER DW, Frank RD, Carter JM, Vierkant RA, et al
    Breast Cancer Risk and Progressive Histology in Serial Benign Biopsies.
    J Natl Cancer Inst. 2017;109.
    >> Share


  22. Restarting Adjuvant Hormone Therapy Improves Breast Cancer Outcomes.
    J Natl Cancer Inst. 2017;109.
    >> Share

  23. HE W, Smedby KE, Fang F, Olsson H, et al
    Treatment Restarting After Discontinuation of Adjuvant Hormone Therapy in Breast Cancer Patients.
    J Natl Cancer Inst. 2017;109.
    >> Share

  24. HERMELINK K, Buhner M, Sckopke P, Neufeld F, et al
    Chemotherapy and Post-traumatic Stress in the Causation of Cognitive Dysfunction in Breast Cancer Patients.
    J Natl Cancer Inst. 2017;109.
    >> Share

  25. ROBSON ME, Reiner AS, Brooks JD, Concannon PJ, et al
    Association of Common Genetic Variants With Contralateral Breast Cancer Risk in the WECARE Study.
    J Natl Cancer Inst. 2017;109.
    >> Share

    September 2017
  26. BYRNE C, Ursin G, Martin CF, Peck JD, et al
    Mammographic Density Change With Estrogen and Progestin Therapy and Breast Cancer Risk.
    J Natl Cancer Inst. 2017;109.
    >> Share

    August 2017
  27. POLLACK CE, Soulos PR, Herrin J, Xu X, et al
    The Impact of Social Contagion on Physician Adoption of Advanced Imaging Tests in Breast Cancer.
    J Natl Cancer Inst. 2017;109.
    >> Share

  28. SCHMIDT MK, van den Broek AJ, Tollenaar RA, Smit VT, et al
    Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women.
    J Natl Cancer Inst. 2017;109.
    >> Share

  29. GINGRAS I, Holmes E, De Azambuja E, Nguyen DH, et al
    Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial.
    J Natl Cancer Inst. 2017;109.
    >> Share

    July 2017
  30. SHAFAEE MN, Ellis MJ
    Breast Cancer Patient-Derived Xenografts: Pros, Cons, and Next Steps.
    J Natl Cancer Inst. 2017;109.
    >> Share

  31. WU X, Ye Y, Barcenas CH, Chow WH, et al
    Personalized Prognostic Prediction Models for Breast Cancer Recurrence and Survival Incorporating Multidimensional Data.
    J Natl Cancer Inst. 2017;109.
    >> Share

  32. ROJAS PA, May M, Sequeira GR, Elia A, et al
    Progesterone Receptor Isoform Ratio: A Breast Cancer Prognostic and Predictive Factor for Antiprogestin Responsiveness.
    J Natl Cancer Inst. 2017;109.
    >> Share

  33. GOETZ MP, Kalari KR, Suman VJ, Moyer AM, et al
    Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer.
    J Natl Cancer Inst. 2017;109.
    >> Share

  34. KUCHENBAECKER KB, McGuffog L, Barrowdale D, Lee A, et al
    Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers.
    J Natl Cancer Inst. 2017;109.
    >> Share

    June 2017
  35. SAMANTA SK, Sehrawat A, Kim SH, Hahm ER, et al
    Disease Subtype-Independent Biomarkers of Breast Cancer Chemoprevention by the Ayurvedic Medicine Phytochemical Withaferin A.
    J Natl Cancer Inst. 2016;109.
    >> Share

  36. DAVE B, Gonzalez DD, Liu ZB, Li X, et al
    Role of RPL39 in Metaplastic Breast Cancer.
    J Natl Cancer Inst. 2016;109.
    >> Share


  37. Higher consumption of grilled, barbecued, and smoked meat linked to increased mortality risk among breast cancer survivors.
    J Natl Cancer Inst. 2017;109.
    >> Share

    May 2017
  38. KERLIKOWSKE K, Gard CC, Tice JA, Ziv E, et al
    Risk Factors That Increase Risk of Estrogen Receptor-Positive and -Negative Breast Cancer.
    J Natl Cancer Inst. 2016;109.
    >> Share

  39. WALTER JR, Xu S, Woodruff TK
    A Call for Fertility Preservation Coverage for Breast Cancer Patients: The Cost of Consistency.
    J Natl Cancer Inst. 2017;109.
    >> Share

    April 2017
  40. NOLAN E, Vaillant F, Visvader JE, Lindeman GJ, et al
    RE: Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
    J Natl Cancer Inst. 2017 Apr 4. doi: 10.1093.
    >> Share

  41. SCHERNHAMMER ES
    RE: Night Shift Work and Breast Cancer Incidence: Three Prospective Studies and Meta-analysis of Published Studies.
    J Natl Cancer Inst. 2017;109.
    >> Share

  42. HANSEN J
    RE: Night Shift Work and Breast Cancer Incidence: Three Prospective Studies and Meta-analysis of Published Studies.
    J Natl Cancer Inst. 2017;109.
    >> Share

  43. ERREN TC, Morfeld P, Gross JV
    RE: Night Shiftwork and Breast Cancer Incidence: Three Prospective Studies and Meta-analysis of Published Studies.
    J Natl Cancer Inst. 2017;109.
    >> Share

  44. STEVENS RG
    RE: Night Shift Work and Breast Cancer Incidence: Three Prospective Studies and Meta-analysis of Published Studies.
    J Natl Cancer Inst. 2017;109.
    >> Share

  45. GARRIDO-CASTRO AC, Winer EP
    Genomic Profiling in Node-Positive ER-Positive Early Breast Cancer: Can Tumor Biology Guide Locoregional Therapy?
    J Natl Cancer Inst. 2017;109.
    >> Share

    March 2017
  46. MA R, Karthik GM, Lovrot J, Haglund F, et al
    Estrogen Receptor beta as a Therapeutic Target in Breast Cancer Stem Cells.
    J Natl Cancer Inst. 2017;109:1-14.
    >> Share

    February 2017
  47. ERIKSEN KT, McElroy JA, Harrington JM, Levine KE, et al
    Urinary Cadmium and Breast Cancer: A Prospective Danish Cohort Study.
    J Natl Cancer Inst. 2016;109.
    >> Share

  48. GREENLEE H, Hershman DL, Shi Z, Kwan ML, et al
    BMI, Lifestyle Factors and Taxane-Induced Neuropathy in Breast Cancer Patients: The Pathways Study.
    J Natl Cancer Inst. 2016;109.
    >> Share

  49. BANEGAS MP, John EM, Slattery ML, Gomez SL, et al
    Projecting Individualized Absolute Invasive Breast Cancer Risk in US Hispanic Women.
    J Natl Cancer Inst. 2016;109.
    >> Share

  50. SINDZINSKI A
    Risk of Heart Disease in Breast Cancer Patients Receiving Estrogen-Deprivation Therapy.
    J Natl Cancer Inst. 2017;109:2-3.
    >> Share

  51. GREENLEE H, Hershman DL, Shi Z, Kwan ML, et al
    BMI, Lifestyle Factors and Taxane-Induced Neuropathy in Breast Cancer Patients: The Pathways Study.
    J Natl Cancer Inst. 2017;109:1-8.
    >> Share

  52. ERIKSEN KT, McElroy JA, Harrington JM, Levine KE, et al
    Urinary Cadmium and Breast Cancer: A Prospective Danish Cohort Study.
    J Natl Cancer Inst. 2017;109:1-7.
    >> Share

  53. SINDZINSKI A
    Risk of Heart Disease in Breast Cancer Patients Receiving Estrogen-Deprivation Therapy.
    J Natl Cancer Inst. 2017;109.
    >> Share

    January 2017
  54. PARADA H JR, Steck SE, Bradshaw PT, Engel LS, et al
    Grilled, Barbecued, and Smoked Meat Intake and Survival Following Breast Cancer.
    J Natl Cancer Inst. 2017 Jan 4. pii: djw299. doi: 10.1093.
    >> Share

  55. KOTSOPOULOS J, Huzarski T, Gronwald J, Singer CF, et al
    Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
    J Natl Cancer Inst. 2016;109.
    >> Share

  56. HILAKIVI-CLARKE L, Warri A, Bouker KB, Zhang X, et al
    Effects of In Utero Exposure to Ethinyl Estradiol on Tamoxifen Resistance and Breast Cancer Recurrence in a Preclinical Model.
    J Natl Cancer Inst. 2016;109.
    >> Share

  57. SMITH BD, Jiang J, Shih YC, Giordano SH, et al
    Cost and Complications of Local Therapies for Early-Stage Breast Cancer.
    J Natl Cancer Inst. 2016;109.
    >> Share

  58. PARKES EE, Walker SM, Taggart LE, McCabe N, et al
    Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer.
    J Natl Cancer Inst. 2016;109.
    >> Share

  59. BENSE RD, Sotiriou C, Piccart-Gebhart MJ, Haanen JB, et al
    Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer.
    J Natl Cancer Inst. 2016;109.
    >> Share

  60. MAMOUNAS EP, Liu Q, Paik S, Baehner FL, et al
    21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy.
    J Natl Cancer Inst. 2017;109.
    >> Share

  61. HAAS JS
    The Complexity of Achieving the Promise of Precision Breast Cancer Screening.
    J Natl Cancer Inst. 2017;109.
    >> Share

  62. SHIEH Y, Eklund M, Madlensky L, Sawyer SD, et al
    Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial.
    J Natl Cancer Inst. 2017;109.
    >> Share


  63. Different Breast Cancer Treatment Options Vary Widely in their Cost-Effectiveness.
    J Natl Cancer Inst. 2017;109:1-2.
    >> Share

    December 2016
  64. TRAVIS RC, Balkwill A, Fensom GK, Appleby PN, et al
    Night Shift Work and Breast Cancer Incidence: Three Prospective Studies and Meta-analysis of Published Studies.
    J Natl Cancer Inst. 2016;108.
    >> Share


  65. Night Shift Work and Breast Cancer Risk.
    J Natl Cancer Inst. 2016;108.
    >> Share

    November 2016
  66. TER BRUGGE P, Kristel P, van der Burg E, Boon U, et al
    Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer.
    J Natl Cancer Inst. 2016;108.
    >> Share

  67. VISVANATHAN K, Yager JD
    Ethnic Variations in Estrogen and Its Metabolites: Sufficient to Explain Differences in Breast Cancer Incidence Rates?
    J Natl Cancer Inst. 2016;108.
    >> Share

    October 2016
  68. MOORE SC, Matthews CE, Ou Shu X, Yu K, et al
    Endogenous Estrogens, Estrogen Metabolites, and Breast Cancer Risk in Postmenopausal Chinese Women.
    J Natl Cancer Inst. 2016;108.
    >> Share

  69. VISVANATHAN K, Yager JD
    Ethnic Variations in Estrogen and Its Metabolites: Sufficient to Explain Differences in Breast Cancer Incidence Rates?
    J Natl Cancer Inst. 2016;108.
    >> Share

    August 2016
  70. MARTIN LJ, Huszti E, Connelly PW, Greenberg CV, et al
    RE: Serum Lipids, Lipoproteins, and Risk of Breast Cancer: A Nested Case-Control Study Using Multiple Time Points.
    J Natl Cancer Inst. 2016;108.
    >> Share

  71. TOOMEY S, Eustace AJ, Pritzker LB, Pritzker KP, et al
    RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
    J Natl Cancer Inst. 2016;108.
    >> Share

  72. SCHMIDT C
    Mammaprint Reveals Who Can Skip Chemotherapy for Breast Cancer.
    J Natl Cancer Inst. 2016;108.
    >> Share

    June 2016
  73. FILLON M
    Continuing To Smoke After Breast Cancer Diagnosis Lowers Survival Rate.
    J Natl Cancer Inst. 2016;108.
    >> Share

    April 2016
  74. AZVOLINSKY A
    Unraveling How Obesity Fuels Cancer.
    J Natl Cancer Inst. 2016;108.
    >> Share

  75. JENKS S
    Digital Imaging of the Breast: Is a Synthetic View Better?
    J Natl Cancer Inst. 2016;108.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016